Thursday, July 10, 2003  Print This | Email This
EU Takes Nations to Court on Patent Laws
By PAUL GEITNER AP Business Writer

BRUSSELS, Belgium (AP) - The EU's head office is taking eight countries to
court over their failure to adapt their national patent laws, saying
Thursday that their lack of cooperation has put the European biotechnology
sector at a "serious disadvantage."

"Adequate patent protection is essential to encourage the investment
required to create jobs and maintain the European Union's competitiveness
in this crucial field," the European Commission said.

After a 10-year debate, the EU adopted what it called "strict ethical
rules" for patenting biotech inventions in 1998 and gave member states
until July 30, 2000, to transpose them into national law.

Germany, Austria, Belgium, France, Italy, Luxembourg, the Netherlands and
Sweden still have not done so, prompting the commission to refer them to
the European Court of Justice.

Their failure to implement the EU directive "has created trade barriers
and hampered the internal market," it said. "Non-implementation ... is
putting the European biotechnology sector at a serious disadvantage."

Seeking to allay public concerns about patenting processes using human
genes or DNA molecules, the rules ban patents for cloning human beings or
modifying their genetic identity, as well as the use of human embryos for
industrial purposes.

The commission said last year that it expects that the global
biotechnology market, not counting agriculture, could amount to more than
euro2 trillion ($2.26 trillion) by 2010.

Yet while Europe has more dedicated biotech companies (1,570) than the
United States (1,273), those in Europe are relatively small, newer and
undercapitalized. The U.S. biotech sector employs 162,000 people, compared
to 61,000 in Europe, and has far more products in the pipeline, according
to EU figures.

Philippe Jacobs of the Flanders Interuniversity Institute for
Biotechnology said uncertainty over patents was "definitely" discouraging
investment in Europe. "For the industry it's really crucial to have patent
protection on their product to have legal certainty," he said.

Reply via email to